Merck

Global pharmaceutical leader. Keytruda (pembrolizumab) is the dominant PD-1 checkpoint inhibitor in oncology with $31.6B+ FY2025 revenue. Gardasil franchise dominates HPV vaccination. Januvia diabetes franchise facing generic erosion but pipeline includes cardiometabolic (sotatercept/WINREVAIR for PAH), vaccines (Capvaxive for pneumococcal), and Welireg (HIF-2α inhibitor).

Merck (NYSE: MRK; MSD ex-US) is a top-5 global pharma. The value drivers are the PD-1 franchise (KEYTRUDA + subcutaneous KEYTRUDA QLEX), the HPV vaccine franchise (GARDASIL/GARDASIL 9), the PAH drug WINREVAIR (sotatercept-csrk), the pneumococcal vaccine CAPVAXIVE, and the newly approved LIPFENDRA (enlicitide, first once-daily oral PCSK9 inhibitor). Two large 2026 acquisitions — Cidara Therapeutics ($9.2B, January, drug-Fc conjugate platform) and Terns Pharmaceuticals ($6.8B, May, MK-4208/formerly TERN-701 oral allosteric BCR::ABL1 TKI) — show Merck re-stocking the oncology pipeline ahead of the ~2028 Keytruda loss of exclusivity.

• monetization model: Product sales — prescription pharmaceuticals/vaccines (one-time/consumable dosing) and animal health; no subscription/SaaS. FY2025 10-K UNKNOWN in source set; FY2024 10-K used. (10-K FY2024; acc. 0000310158-25-000013, Item 1)
• revenue mix: Pharmaceutical ~89% (Keytruda ~46% of total; Gardasil ~13%); Animal Health ~9%; Other ~1%. (same 10-K, Segment/Revenue notes)
• who pays: Third-party payers (commercial insurers, PBMs, Medicare/Medicaid, national health systems) and patients; wholesalers/distributors as intermediaries. (same 10-K, Item 1)
• margin_value_capture: Gross margin ~76%; high R&D/SG&A; value accrues to patented therapeutics. (same 10-K, Consolidated Statements of Income)

• customer classes: Payers & Insurers, Health Systems & Providers, plus wholesalers/distributors and veterinarians/producers. (10-K FY2024; acc. 0000310158-25-000013, Item 1)

Merck & Co., Inc. is a global pharmaceutical and animal-health company. Its business model is dominated by a single oncology biologic, Keytruda (pembrolizumab), plus vaccines, diabetes products, hospital acute-care products, and animal-health products.

For fiscal 2024, Merck reported total sales of $64,168 million.[S1]

The pharmaceutical segment is not a single product story. The largest disclosed product in the FY2024 10-K is Keytruda at $29,482M, about 45.9% of total company revenue.[S1] The next largest is Gardasil / Gardasil 9 at $8,559M, about 13.3% of total revenue.[S1] This is an extreme concentration risk: two products account for roughly 59% of total revenue. The concentration becomes even more acute when measured by profit contribution because oncology biologics and vaccines carry higher gross margins than mature small-molecule products.

The 10-K segment presentation is required under U.S. GAAP. The financial statement footnotes and Item 7 MD&A are the correct primary source for segment split. The exact percentages above are derived from the figures I can recall; they should be re-computed directly from the FY2024 10-K segment table. If the exact Pharmaceutical figure differs by a few hundred million, the concentration conclusion does not materially change.

Merck does not disclose per-patient or per-vial unit economics in its 10-K, so any unit-level calculation is derived. The most decision-relevant calculation is a revenue-concentration and earnings-sensitivity bridge for Keytruda.

Merck makes money by selling patented medicines, vaccines, and animal-health products to wholesalers, distributors, governments, hospitals, clinics, pharmacies, and veterinary providers. The ultimate payers are typically private insurers, government payers such as Medicare and Medicaid, and patients through copayments and deductible exposure.[S1] In the U.S., Merck sells pharmaceutical products primarily to wholesale distributors, retailers, hospitals, government agencies, and managed-health-care providers.[S1]

The 10-K’s revenue-recognition disclosure states that revenue is recognized when control transfers to the customer; the transaction price may include variable consideration such as rebates, chargebacks, discounts, and returns.[S1] That variable consideration is material for U.S. commercial and Medicare/Medicaid pricing. Merck participates in Medicaid Drug Rebate, Medicare coverage-gap discount, 340B, VA/FSS, and other statutory programs.[S1] These programs lower net realized price relative to list price.

• Private insurers and PBMs: pay for covered outpatient drugs; manufacturers provide rebates and chargebacks.
• Medicare Part B / Part D: Keytruda is primarily a Part B physician-administered drug; Medicare pays under ASP-based reimbursement; Januvia/Janumet are Part D retail drugs.
• Medicaid: receives statutory rebates.
• International governments: pay through national health systems, tenders, or price-regulated reimbursement.
• Patients: pay cost-sharing, coinsurance, or cash.

This payer structure means Merck’s pricing power is not raw list-price power; it is net-price power after statutory and commercial rebates.

Merck’s 10-K commonly describes customer concentration in the U.S. pharmaceutical distribution channel, where three large wholesalers account for a material portion of trade receivables or sales. The three U.S. wholesalers are typically McKesson Corporation, Cencora, Inc. (formerly AmerisourceBergen), and Cardinal Health, Inc.[S1] I am not confident enough in the exact percentage figure from the FY2024 10-K to state it here; it should be read directly from the MD&A credit-risk/customer-concentration disclosure. The exact percentage and the named-counterparty list are needs primary source validation.

This concentration is consistent with the broader U.S. pharmaceutical distribution model and with competitor 10-K disclosures, but the Merck-specific percentage should not be quoted from memory.

Merck’s customer base is not the patient; it is the payer and distribution system that reimburses and delivers the drug.

• U.S. wholesale distributors: Merck sells pharmaceutical products primarily to wholesale distributors, retailers, hospitals, government agencies, and managed health care providers.[S1]
• Retail and hospital pharmacies: for oral products such as Januvia/Janumet and certain vaccines.
• Hospitals and oncology infusion centers: for Keytruda and other injectable hospital products.
• Federal and state government programs: Medicare, Medicaid, 340B hospitals, VA, and public health systems.
• International governments and public-health agencies: for vaccines and infectious-disease products.
• Veterinarians and animal producers: for animal-health products.

The oncologist is a critical influencer but not the payer. Keytruda’s buying decision is shaped by clinical guidelines, formulary access, and reimbursement convenience. Merck’s marketing and medical affairs effort is aimed at oncologists and hospital pharmacy-and-therapeutics committees.

The vaccine buyer is often a public-health system, a pediatric or primary-care practice, or a pharmacy; the decision is heavily influenced by ACIP/CDC recommendations and school-entry requirements.

The diabetes buyer is a prescriber, but the payer and formulary position now determine Januvia/Janumet demand more than physician preference because DPP-4 inhibitors are a mature, heavily substituted class.

Merck’s 10-K contains risk-factor language on customer concentration, government price regulation, and payer consolidation.[S1] That language is the best evidence that Merck itself views concentrated wholesale and government-payer customers as a structural risk.

The 10-K typically identifies the largest U.S. wholesalers by name in its concentration disclosure. I recall those names as McKesson, Cencora, and Cardinal Health, but the exact percentage and paragraph should be verified against the filed document.[S1] If the FY2024 10-K does not name them in the MD&A risk section, then the named-customer claim is needs primary source validation.

Q2 2026 total worldwide sales $16.607B (+5% YoY, +4% ex-FX). H1 2026 sales $32.893B. FY2025 sales $65.011B. Q2 2026 gross profit $12.212B = 73.5% gross margin (revenue $16.607B − COGS $4.395B). Q2 2026 GAAP net loss −$1.335B (vs +$4.427B YoY) driven by the $5.7B Terns IPR&D charge; GAAP EPS −$0.54 vs +$1.76 YoY. H1 2026 GAAP net loss −$5.575B.

Intervene layer (Context). Classic toll-road customer: massive pharma R&D engine that spends on Measure, Read, Prove, Manufacture, and Package & Deliver infrastructure. Keytruda's patent cliff (~2028) is the dominant risk/reward catalyst. Not a bottleneck supplier — a demand engine for the toll roads.

Merck is the Intervene-layer demand engine, not a bottleneck supplier. The investable thesis for the healthspan toll-road machine is that a $65B-revenue pharma with a 73.5% gross margin and $9.3B H1 operating cash flow will keep funding the Measure / Prove / Manufacture / Package-&-Deliver suppliers upstream. The Keytruda LOE (~2028) is the single largest threat to that demand engine — which is precisely why the Terns and Cidara deals matter: they are Merck spending ~$16B to defend a ~$34B oncology franchise before the cliff hits.

1. Keytruda concentration + LOE exposure.

• Keytruda FY2025 sales $31.641B ÷ total FY2025 sales $65.011B = 48.7% of revenue (EX-99.1 segment table).
• Q2 2026 Keytruda $7.906B was −1% YoY (already flatlining two years ahead of LOE). KEYTRUDA QLEX (SC) added $463M in Q2 — the SC franchise is the LOE-defensive conversion play.
• US is ~55% of Keytruda revenue (10-K geographic split, prior-year). → ~$17.4B of US Keytruda revenue ($31.6B × 0.55) sits inside the ~2028 exclusivity window. A biosimilar/LOE cliff that erodes even 50% of US Keytruda = ~$8.7B annual revenue at risk — more than the entire H1 2026 WINREVAIR + CAPVAXIVE + LIPFENDRA combined (~$1.6B annualized).

2. "Cost of moat vs moat defended" — Terns acquisition.

• Terns = $6.8B cash consideration ($5.842B net of cash acquired). Merck recorded $5.7B as immediate IPR&D expense = 84% of the purchase price expensed in the quarter, with $1.1B net assets booked.
• Moat defended = the oncology franchise (~$33.8B Keytruda + Lynparza + Welireg alliance revenue, FY2025). Acquisition spend ÷ defended franchise = $6.8B ÷ $33.8B = 0.20× — Merck is paying ~20 cents per dollar of oncology revenue to extend the franchise's life via MK-4208 (oral allosteric BCR::ABL1 TKI, Phase 3 for CML post-prior-TKI).

3. Clean (ex-one-time) EPS power.

• Q2 2026 non-GAAP EPS −$0.13 includes the $2.31 Terns charge (both GAAP and non-GAAP include it). Adding back $2.31 → clean non-GAAP EPS ≈ +$2.18, vs Q2 2025 GAAP EPS +$1.76 → +24% YoY clean earnings power, hidden under the −$0.54 GAAP headline.

4. Capital structure / cash burn.

• H1 2026 OCF $9.288B − capex $1.884B = H1 FCF $7.404B.
• M&A cash outflow H1 2026 = $8.779B (Cidara) + $5.842B (Terns) = $14.621B — ~2.0× H1 FCF.
• Cash fell $14.565B → $6.849B (−53%) over six months. LT debt rose $46.75B → $51.081B (noncurrent) + $2.3B current = $53.4B total LT debt. Net debt = $53.4B − $6.85B = $46.5B, vs stockholders' equity $41.93B → net debt/equity 1.11×.
• Financing: $6.0B 364-day term loan drawn and repaid + $6.0B senior notes issued May 2026 (10-Q Note).